75-84
Long-Term Follow-up of Autologous Fibroblast Transplantation for Facial Contour Deformities, A Non-Randomized Phase IIa Clinical Trial
Authors: Amir Bajouri, Zahra Orouji, Ehsan Taghiabadi, Abdoreza Nazari, Atefeh Shahbazi, Nasrin Fallah, Parvaneh Mohammadi, Mohammad Rezvani, Zahra Jouyandeh, Fatemeh Vaezirad, Zahra Khalajasadi, Mahshid Ghasemi, Aslan Fanni, Sara Haji Hosseinali, Ahad Alizadeh, Hossein Baharvand, Saeed Shafieyan, Nasser Aghdami

Number of views: 362
Objective: Recently, the promising potential of fibroblast transplantation has become a novel modality for skin
rejuvenation. We investigated the long-term safety and efficacy of autologous fibroblast transplantation for participants
with mild to severe facial contour deformities.
Materials and Methods: In this open-label, single-arm phase IIa clinical trial, a total of 57 participants with wrinkles
(n=37, 132 treatment sites) or acne scars (n=20, 36 treatment sites) who had an evaluator’s assessment score of
at least 2 out 7 (based on a standard photo-guide scoring) received 3 injections of autologous cultured fibroblasts
administered at 4-6 week intervals. Efficacy evaluations were performed at 2, 6, 12, and 24 months after the final
injection based on evaluator and patient’s assessment scores.
Results: Our study showed a mean improvement of 2 scores in the wrinkle and acne scar treatment sites. At sixth
months after transplantation, 90.1% of the wrinkle sites and 86.1% of the acne scar sites showed at least a one grade
improvement on evaluator assessments. We also observed at least a 2-grade improvement in 56.1% of the wrinkle
sites and 63.9% of the acne scar sites. A total of 70.5% of wrinkle sites and 72.2% of acne scar sites were scored as
good or excellent on patient assessments. The efficacy outcomes remained stable up to 24-month. We did not observe
any serious adverse events during the study.
Conclusion: These results have shown that autologous fibroblast transplantation could be a promising remodeling
modality with long-term corrective ability and minimal adverse events (Registration Number: NCT01115634).